PMID- 12065522
OWN - NLM
STAT- MEDLINE
DCOM- 20020730
LR  - 20210526
IS  - 0019-9567 (Print)
IS  - 1098-5522 (Electronic)
IS  - 0019-9567 (Linking)
VI  - 70
IP  - 7
DP  - 2002 Jul
TI  - In vivo effects of a synthetic 2-kilodalton macrophage-activating lipopeptide of 
      Mycoplasma fermentans after pulmonary application.
PG  - 3785-92
AB  - Mycoplasmas can cause interstitial pneumonias inducing critical illness in humans 
      and animals. Mycoplasma infections are characterized by an influx of neutrophils, 
      followed by an accumulation of macrophages and lymphocytes. The present study 
      deals with the question of which mycoplasmal components cause this host reaction. 
      The mycoplasma-derived, macrophage-activating lipopeptide 2S-MALP-2 was used to 
      mimic the sequelae of a mycoplasma infection. To this end, 2S-MALP-2 was 
      intratracheally instilled into the lungs of Lewis rats, and the bronchoalveolar 
      lavage cells were examined at different times after different doses of 2S-MALP-2. 
      Application of 2.5 microg induced a pronounced leukocyte accumulation in the 
      bronchoalveolar space. At 24 h after 2S-MALP-2 administration, the majority of 
      leukocytes consisted of neutrophils, followed by macrophages, peaking on days 2 
      and 3. Lymphocyte numbers, although amounting to only a few percent of the total 
      bronchoalveolar lavage cells, also increased significantly, with maximal 
      lymphocyte accumulation occurring by 72 h after instillation. The leukocyte count 
      of the lung interstitium was increased on day 3 after treatment. After 10 days 
      all investigated cell populations returned to control levels. Transient 
      chemotactic activity for neutrophils was detected in the bronchoalveolar lavage 
      fluid early after 2S-MALP-2 application, followed by monocyte chemoattractant 
      protein-1 activity (MCP-1) in lung homogenates. MCP-1 was produced by 
      bronchoalveolar lavage cells upon stimulation with 2S-MALP-2. Our data indicate 
      that mycoplasmal lipoproteins and lipopeptides are probably the most relevant 
      mycoplasmal components for the early host reaction. The primary target cells are 
      likely to be the alveolar macrophages liberating chemokines, which attract 
      further leukocytes.
FAU - Luhrmann, Anke
AU  - Luhrmann A
AD  - Department of Functional and Applied Anatomy, Medical School of Hannover, 30623 
      Hannover, Germany. luehrmann.anke@mh.hannover.de
FAU - Deiters, Ursula
AU  - Deiters U
FAU - Skokowa, Julia
AU  - Skokowa J
FAU - Hanke, Michaela
AU  - Hanke M
FAU - Gessner, Johannes E
AU  - Gessner JE
FAU - Muhlradt, Peter F
AU  - Muhlradt PF
FAU - Pabst, Reinhard
AU  - Pabst R
FAU - Tschernig, Thomas
AU  - Tschernig T
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Infect Immun
JT  - Infection and immunity
JID - 0246127
RN  - 0 (Bacterial Proteins)
RN  - 0 (Chemokine CCL2)
RN  - 0 (Chemokine CCL5)
RN  - 0 (Interleukin-16)
RN  - 0 (Lipopeptides)
RN  - 0 (Lipoproteins)
RN  - 0 (Oligopeptides)
RN  - DZX5IUA94D (macrophage stimulatory lipopeptide 2)
SB  - IM
MH  - Animals
MH  - Bacterial Proteins/administration & dosage/chemical synthesis/*immunology
MH  - Bronchoalveolar Lavage
MH  - Cell Count
MH  - Chemokine CCL2/immunology
MH  - Chemokine CCL5/administration & dosage
MH  - Chemotaxis, Leukocyte/immunology
MH  - Dose-Response Relationship, Drug
MH  - Interleukin-16/administration & dosage
MH  - Leukocytes/cytology/immunology
MH  - Lipopeptides
MH  - Lipoproteins/administration & dosage/chemical synthesis/*immunology
MH  - Lung/*immunology
MH  - Lymphocytes/cytology
MH  - Macrophage Activation/*immunology
MH  - Macrophages, Alveolar/cytology/*immunology
MH  - Male
MH  - Mice
MH  - Mice, Inbred C57BL
MH  - Mycoplasma fermentans/*immunology
MH  - Neutrophils/immunology
MH  - Oligopeptides/administration & dosage/chemical synthesis/*immunology
MH  - Rats
MH  - Rats, Inbred BN
MH  - Rats, Inbred Lew
MH  - Stereoisomerism
MH  - Time Factors
MH  - Trachea/immunology
PMC - PMC128036
EDAT- 2002/06/18 10:00
MHDA- 2002/07/31 10:01
PMCR- 2002/07/01
CRDT- 2002/06/18 10:00
PHST- 2002/06/18 10:00 [pubmed]
PHST- 2002/07/31 10:01 [medline]
PHST- 2002/06/18 10:00 [entrez]
PHST- 2002/07/01 00:00 [pmc-release]
AID - 0014 [pii]
AID - 10.1128/IAI.70.7.3785-3792.2002 [doi]
PST - ppublish
SO  - Infect Immun. 2002 Jul;70(7):3785-92. doi: 10.1128/IAI.70.7.3785-3792.2002.